<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1648096</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of daphnetin combined with tobramycin on <italic>Pseudomonas aeruginosa</italic> biofilm infection <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Dingbin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1369947/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Mao</surname>
<given-names>Chao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Siyuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Zhongwei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Weilin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhencong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2404364/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Liangsheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Chaoqin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2178118/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Weixiong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wei</surname>
<given-names>Jinsong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2811664/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wei</surname>
<given-names>Qingjun</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University</institution>, <addr-line>Zhanjiang, Guangdong</addr-line>,&#xa0;<country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Orthopedics, The Second Affiliated Hospital of Guangxi Medical University</institution>, <addr-line>Nanning, Guangxi</addr-line>,&#xa0;<country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ren Jing, Shenzhen University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Haigang Li, Changsha Medical University, China</p>
<p>Yongfei He, Sun Yat-sen University, China</p>
<p>Xingxiang Duan, Renmin Hospital of Wuhan University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Qingjun Wei, <email xlink:href="mailto:weiqingjungxnn@163.com">weiqingjungxnn@163.com</email>; Jinsong Wei, <email xlink:href="mailto:jinsong.wei@gdmu.edu.cn">jinsong.wei@gdmu.edu.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1648096</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>07</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Li, Mao, Chen, Wang, Zhang, Li, Li, He, Guo, Wei and Wei.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Li, Mao, Chen, Wang, Zhang, Li, Li, He, Guo, Wei and Wei</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The aim of this study was to investigate the effectiveness of daphnetin in combination with tobramycin on <italic>Pseudomonas aeruginosa</italic> biofilm infection <italic>in vitro</italic> and <italic>in vivo</italic>.</p>
</sec>
<sec>
<title>Method</title>
<p>The study was divided into four groups: control, tobramycin, daphnetin, and tobramycin combined with daphnetin groups. First, a 72-h <italic>Pseudomonas aeruginosa</italic> biofilm model was established <italic>in vitro</italic>. The antibacterial effects of daphnetin and tobramycin alone and in combination were evaluated using various methods, including microdilution, crystal violet staining, colony counting, and electron microscopy. Then, a model of <italic>Pseudomonas aeruginosa</italic> biofilm infection in rabbit joints was established <italic>in vivo</italic>. After 7 days of continuous treatment, the rabbits were sacrificed on day 14 post infection. The therapeutic effect of daphnetin and/or tobramycin was further evaluated by observing the gross anatomy of the knee joint, biofilm PNA-FISH, synovial bacterial load, and pathology.</p>
</sec>
<sec>
<title>Results</title>
<p>The results showed that daphnetin had a minimum inhibition concentration (MIC) of 890 &#xb5;g/mL against the PAO1 strain, while tobramycin had an MIC of 2.75 &#xb5;g/mL against the same strain. Crystal violet staining and colony counting showed that the biofilm in the group treated with both daphnetin and tobramycin was significantly less than that in the control group (P &lt; 0.05). Scanning electron microscopy further confirmed that the combination of daphnetin and tobramycin had the strongest bactericidal effect. <italic>In vivo</italic>, the knee joint of rabbits in the daphnetin combined with tobramycin group had the least gross anatomical inflammatory response, amount of PNA-FISH biofilm, synovial colony count, synovial pathological examination of inflammatory cell infiltration, and synovial thickening.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The study indicated that daphnetin may be a promising synergist that enhances the activity of tobramycin against <italic>Pseudomonas aeruginosa</italic> biofilm infection <italic>in vitro</italic> and <italic>in vivo</italic>.</p>
</sec>
</abstract>
<kwd-group>
<kwd>daphnetin</kwd>
<kwd>biofilm</kwd>
<kwd>tobramycin</kwd>
<kwd>
<italic>Pseudomonas aeruginosa</italic>
</kwd>
<kwd>combination</kwd>
</kwd-group>
<counts>
<fig-count count="10"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="44"/>
<page-count count="13"/>
<word-count count="6062"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Innate Immunity</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Suppurative arthritis (SA) is a condition in which an infection in the joint space destroys the articular cartilage, causes synovitis, and impairs joint function (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Current treatments for SA include antibiotic therapy and surgery (<xref ref-type="bibr" rid="B3">3</xref>). However, bacterial resistance poses a challenge to the treatment of SA, and antibiotic tolerance is one of the reasons for drug resistance. Pathogenic bacteria can develop antibiotic tolerance through mechanisms such as biofilm (BF) formation (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). <italic>Pseudomonas aeruginosa</italic> (PA) is one of the major bacteria responsible for nosocomial infections in SA (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>PA is an opportunistic gram-negative pathogen that can thrive in different ecological environments and hospital conditions because of its extraordinary metabolic diversity, genomic plasticity, resistance to environmental stress, natural resistance to antibiotics, strong ability to form BF, and quorum sensing (QS) systems that regulate the expression of virulence factors (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). The World Health Organization has classified PA as a &#x201c;key priority pathogen&#x201d; because of its resistance to broad-spectrum antibiotics, including third-generation cephalosporins and carbapenems (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). PA has two survival modes: planktonic bacteria and BF. PA-BF is a microbial aggregate formed by PA adhering to the surface of the medium through its secreted extracellular polymeric matrix and enveloping itself (<xref ref-type="bibr" rid="B11">11</xref>). It is known that more than 80% of PA infections are associated with PA-BF (<xref ref-type="bibr" rid="B12">12</xref>). Once formed, PA-BF reduces immune cell and antibiotic damage to bacteria, leading to clinically refractory infections (<xref ref-type="bibr" rid="B13">13</xref>). One literature report indicated that the multidrug resistance rate of PA was 88.3%, among which 30.1% were extensively drug-resistant. The resistance rates to ceftazidime and ciprofloxacin were 75.0% and 46.6%, respectively (<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>BF formation has been reported in keratitis (<xref ref-type="bibr" rid="B15">15</xref>), empyema (<xref ref-type="bibr" rid="B16">16</xref>), tonsillitis (<xref ref-type="bibr" rid="B17">17</xref>), and otitis media (<xref ref-type="bibr" rid="B18">18</xref>). In a previous study, PAO1, a PAO1<italic>&#x394;wspF</italic> strain with high expression of c-di-GMP and a PAO1/<italic>p<sub>lac</sub>-yhjH</italic> strain with low expression of c-di-GMP were used to successfully construct three PA-BF models of SA (<xref ref-type="bibr" rid="B19">19</xref>). Owing to the excessive use of antibiotics, PA has developed high resistance to antibiotics, which poses difficulties for clinical anti-infective treatment. Combination therapy has become a research hotspot in anti-infective treatment (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>) and can alleviate the pressure of clinical treatment. Daphnetin (DAP) is a traditional Chinese medicine and a natural coumarin derivative that can inhibit the growth of <italic>Staphylococcus aureus (</italic>
<xref ref-type="bibr" rid="B22">22</xref>), inhibit the BF of <italic>Ralstonia solanacearum (</italic>
<xref ref-type="bibr" rid="B23">23</xref>), and inhibit and destroy the BF of PA (<xref ref-type="bibr" rid="B24">24</xref>). DAP lacks toxicity in animal models (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>) and is used clinically as an adjuvant therapy for thromboangiitis obliterans and other occlusive vascular diseases and coronary heart disease. Aminoglycosides are widely used in clinical practice and have broad-spectrum activity against bacteria, including PA. However, with the increasing use of these drugs in clinical practice, the frequency of drug-resistant strains has increased. Because BF formation is an important reason for antibiotic failure/bacterial resistance (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>), destruction of biofilm can enhance the effectiveness of antibiotics. It has been reported that DAP has the effect of destroying biofilm (<xref ref-type="bibr" rid="B24">24</xref>). This study investigated the effect of DAP combined with tobramycin (TOB) in the treatment of PA-BF infection <italic>in vitro</italic> and <italic>in vivo</italic>, providing a new direction for the clinical treatment of PA-resistant infections.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Determination of minimum inhibitory concentration and minimal bactericidal concentration</title>
<p>The MIC of DAP or TOB (Beijing Solaibao Technology Co., Ltd., Beijing, China) or ethylenediaminetetraacetic acid disodium (EDTA-2Na) (Shanghai Test One Chemical Reagent Co., Ltd., Shanghai, China) against the experimental strain was determined using the method described by Belanger et&#xa0;al (<xref ref-type="bibr" rid="B27">27</xref>). The PA PAO1 wild-type strain was obtained from the Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). To prepare the P8 bacterial solution, 1&#x2013;3 pure colonies were selected and cultured on agar plates overnight. The colonies were then further cultured with M&#xfc;ller-Hinton broth (Qingdao Hopebio Biotechnology Co. Ltd., Qingdao, China) at 37&#xb0;C and 220 rpm for 14&#x2013;16 h. The resulting bacterial solutions were centrifuged at 3,000 rpm for 15 min using a centrifuge from HERMLE Labortechnik GmbH (Germany), and any residual media components were removed. The strains were then thoroughly washed three times with phosphate buffer solution (PBS). The concentration of the bacterial solution was adjusted to 1.0 &#xd7; 10<sup>8</sup> CFU/mL (OD<sub>600</sub> = 0.1) using a spectrophotometer (UV-Visible Spectrophotometer T6, Beijing Purse General Instrument Co. Ltd., Beijing, China). DAP (Shanghai Macklin Biochemical Co. Ltd., Shanghai, China) was dissolved in dimethyl sulfoxide (DMSO) (Beijing Solarbio Science Technology Co. Ltd., Guangzhou, China), while TOB was dissolved in normal saline. Different final concentrations of DAP and TOB solutions were prepared (the DMSO solvent was diluted at least 100-fold). Approximately 95 &#x3bc;L of the mixture was added to each well of a 96-well cell culture dish, followed by the addition of 5 &#x3bc;L (OD<sub>600</sub> = 0.01) of the bacterial solution to each well, with three wells being repeated. In addition, a negative control group (without bacterial solution) and a positive control group (without drugs) were established. The 96-well cell culture dish was placed in a biochemical incubator (HPX-400, Shanghai Yuejin Medical Equipment Co. Ltd., Shanghai, China) at 37&#xb0;C for 18 h. Finally, the MIC was determined based on the turbidity of the culture. Then, the wells where the concentration was greater than or equal to MIC were incubated at 37&#xb0;C for an extra 24 h. The concentration at which there was still no visible growth was defined as the MBC (<xref ref-type="bibr" rid="B30">30</xref>).The experiment was repeated three times.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Quantitative BF by crystal violet staining <italic>in vitro</italic>
</title>
<p>The following method, developed by Haney et&#xa0;al. (<xref ref-type="bibr" rid="B31">31</xref>), was used as a reference. A P8 bacterial solution was prepared and 200 &#x3bc;L of the bacterial solution was added to each well of a 96-well cell culture dish. The medium was changed every other day and cultured at 37&#xb0;C for 72 h. Before treatment, the OD<sub>600</sub> value of the bacterial solution was measured using a microplate reader. The suspended bacterial solution of each well was then discarded and the BF was gently washed three times with PBS solution, leaving only the adherent growth BF. <italic>In vitro</italic> experiments were divided into the following groups: control group (same amount of medium added without drugs), DMSO group (solvent DMSO diluted 100 times, solvent only), drug group: DAP group (890 &#x3bc;g/mL), TOB group (5.5 &#x3bc;g/mL), EDTA-2Na (2 mg/mL) + TOB (5.5 &#x3bc;g/mL), and DAP (890 &#x3bc;g/mL) + TOB (5.5 &#x3bc;g/mL) group. EDTA-2Na served as a positive control for the experimental treatment. Different groups of 200 &#x3bc;L drugs were added to 96-well cell culture dishes and further cultured at 37&#xb0;C for 24 h. The supernatant of each well was discarded, and the BF was gently washed three times with PBS solution and then dried at room temperature. A 96-well cell culture dish was stained with 220 &#x3bc;L of 1% crystal violet (100 mL, Beijing Solarbio Science &amp; Technology Co. Ltd., Beijing, China) at room temperature for 30 min. The dye was then poured out, the dish was gently washed three times with pure water and then left to dry (usually for 24 h). A total of 220 &#x3bc;L of 33% glacial acetic acid was added to the 96-well cell culture dish and dissolved at room temperature for 20 min. The OD value was measured at a wavelength of 595 nm using a microplate reader (3020, Thermo Fisher Scientific Oy, Finland).</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>BF colony count</title>
<p>To determine the concentration of bacteria, the method of He et&#xa0;al. (<xref ref-type="bibr" rid="B32">32</xref>) was used. After drug treatment, the supernatant of the original well was removed and the BF was washed three times with PBS solution. Then 100 &#x3bc;L of 0.1% Triton X-100 was added to the well and sonicated for 5 min using a JP-031S sonicator. The resulting bacterial suspension was diluted tenfold using serial dilution and spread evenly on an LB agar plate. After 24 h of incubation at 37&#xb0;C, the CFU count was performed and the bacterial concentration was calculated. Finally, the results were recorded as logarithmic values with 10 as the base.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Destructive effect of drugs on PA-BF observed using scanning electron microscopy</title>
<p>To prepare the BF carrier, a circle of 1 cm diameter was cut from a 0.3-mm thick polyvinyl chloride (PVC). This circle was soaked in 75% alcohol for one night and then rinsed three times with sterile 0.9% normal saline (NS) to obtain the BF carrier. Next, 1,000 &#x3bc;L of P8 solution was added to a 24-well cell culture dish. Four holes were made and the BF carrier was placed in each hole, ensuring that it was completely immersed in the bacterial solution. The dish was then cultured at 37&#xb0;C for 72 h. The medium was changed every other day and surface planktonic bacteria were removed by rinsing with sterile PBS water. <italic>In vitro</italic> experiments were conducted using fine groups: control, drug group (890 &#x3bc;g/mL DAP), TOB group (5.5 &#x3bc;g/mL), EDTA-2Na (2 mg/mL) + TOB (5.5 &#x3bc;g/mL), and DAP + TOB group (890 &#x3bc;g/mL DAP + 5.5 &#x3bc;g/mL TOB). One thousand microliters of the respective drug solutions were added to 24-well cell culture dishes and cultured at 37&#xb0;C for 24 h. After 24 h, the supernatant of each well was discarded and the BF carrier was gently washed three times with PBS solution. It was then placed in 2.5% glutaraldehyde fixative and fixed at 4&#xb0;C for 12 h. After the removal of the glutaraldehyde, the BF carrier was rinsed with PBS three times for 5 min each time. The BF carrier was dehydrated through a series of ethanol concentrations (30% &#x2192; 50% &#x2192; 60% &#x2192; 70% &#x2192; 80% &#x2192; 90%) for 10 min each time. It was then dehydrated twice in 100% ethanol for 10 min each time. The samples were dried in a vacuum freeze dryer for 24 h and then sprayed with gold using the ion sputtering coating method. Finally, the samples were observed and photographed under the SEM. Finally, we performed quantitative analysis of electron microscopy images using Image-Pro Plus 6.0 software (Image-Pro Plus 6.0, Media Cybernetics, USA).</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>
<italic>In vivo</italic> experimental animals and grouping</title>
<p>Healthy and clean New Zealand rabbits, aged 3&#x2013;4 months, provided by the Experimental Animal Centre of Guangxi Medical University were used in this study. One week before the experiment, each rabbit was placed in an individual cage and provided with water and antibiotic-free rabbit food (80&#x2013;100 g) at a temperature of 18&#x2013;25&#xb0;C with air circulation and 40&#x2013;70% relative humidity. The rabbits (n = 16) were randomly divided into four groups using a random number table. These groups were the control group (which received the same amount of sterile saline without drugs), the DAP group (which received 890 &#x3bc;g/mL), the TOB group (which received 5.5 &#x3bc;g/mL), and the TOB + DAP group (which received both drugs at the same concentration as the other groups). The study was approved by the Medical Ethics Committee of Guangxi Medical University, and all animal experiments were conducted following the committee&#x2019;s guidelines.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Rabbit knee joint inoculation</title>
<p>To prepare the bacterial inoculation solution, the P8 bacterial solution was first prepared. This was then diluted 10-fold to a concentration of 10<sup>6</sup> and set aside. For anesthesia, the rabbits were placed in a rabbit box and slowly injected intravenously with 10% chloral hydrate (5 g/50 mL) X mL (200 mg/kg). For inoculation, the rabbits were fully anesthetized and placed on an operating table in the supine position. Next, the skin of the right knee was prepared with a standard iodophor disinfectant wipe. The knee was then flexed and the patellar ligament and the lateral space between the proximal tibia and distal femur were palpated. Next, 1 mL of the inoculum was injected using a 5 mL syringe. The rabbits were fed routinely for 6 days after inoculation.</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>Treatment of pyogenic knee arthritis in rabbits</title>
<p>On day 7 of the experiment, two rabbits were randomly selected from each group. Synovial fluid was collected from the infected knee joint for bacterial culture and drug susceptibility testing. The rabbits in each group were injected with one of the following: saline, DAP 890 &#x3bc;g/mL, TOB 5.5 &#x3bc;g/mL, or a combination of DAP 890 &#x3bc;g/mL and TOB 5.5 &#x3bc;g/mL in a 1 mL solution. In addition, rabbits in each group received an intramuscular injection of TOB (10 mg/kg/d) for seven consecutive days to treat any systemic infections.</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Anatomy of the rabbit knee joint</title>
<p>On day 14, the rabbits were euthanized using intravenous injection of a lethal dose (200 mg/kg) of 20% chloral hydrate (10 g/50 mL). Samples were then collected by moving the rabbit to the operating table and placing it in the supine position. The right knee joint was disinfected with iodophor and an anterior median incision of approximately 6 cm was made. The skin, subcutaneous tissue, superficial fascia, and deep fascia were incised in sequence. The distal insertion of the patellar ligament was then cut to expose the entire joint space. The results were then photographed. The exudate, debris, and prepatellar synovium in the joint cavity were collected. Additionally, we monitored rabbit body weights and measured serum alanine aminotransferase (ALT) and creatinine levels on days 1, 7, and 14 to evaluate systemic drug toxicity.</p>
</sec>
<sec id="s2_9">
<label>2.9</label>
<title>Observation and quantification of BF flocs using peptide nucleic acid fluorescence <italic>in situ</italic> hybridization</title>
<p>The PNA-FISH kit (AdvanDx, MA, USA) and the method described in previous literature (<xref ref-type="bibr" rid="B33">33</xref>) were used, with some improvements. Sample preparation: We weighed 0.15 g of flakes and rinsed them three times with a sterile PBS solution. We then added 500 &#x3bc;L of PBS solution and homogenized the flocs three times using a grinding machine (sample freezing grinding instrument; Guangzhou Luca Sequencing Instrument Co. Ltd., Guangzhou, China) for 1 min each time at a speed of 70 Hz/s to obtain the homogenate. Slide preparation: Slides were immersed in 75% alcohol for 30 min and then rinsed three times with a sterile PBS solution. We placed 20 &#x3bc;L of homogenized droplets on the slide, evenly coated it with a gun head, and dried it. Then, 10 &#x3bc;L droplets of the <italic>Pseudomonas aeruginosa</italic>-specific PNA probe were placed on the slide in the dark, covered with coverslips, and sealed with rubber. The slides were placed in a humidity box and hybridized in an incubator at 55&#xb0;C for 60 min. We then removed the rubber and coverslip in the dark, immersed the slide in pure water at 55&#xb0;C for 30 min, and dried it. We added 10 &#xb5;L of DAPI staining solution for 15 min. Finally, we used a fluorescence microscope (EVOS FL Auto 2, Invitrogen by Thermo Fisher Scientific, USA) to observe and analyze the image acquisition. After imaging, we used analysis software (Image-Pro Plus 6.0, Media Cybernetics, USA) to measure the red fluorescence area in each film (to select the value of the maximum red area).</p>
</sec>
<sec id="s2_10">
<label>2.10</label>
<title>Flocs colony count</title>
<p>The 0.15 g flocs were washed three times with a sterile PBS solution. Then 500 &#xb5;L of the sterile PBS solution was added. The flocs were homogenized three times for 1 min at a speed of 70 Hz/s using a grinding machine. The colonies of each sample were then counted using a continuous tenfold dilution method. Finally, the results were recorded as Xg (CFU/mL) based on the weight, bacterial load, and fluid volume of each sample.</p>
</sec>
<sec id="s2_11">
<label>2.11</label>
<title>Histopathological examination of the rabbit knee joint using hematoxylin and eosin (H&amp;E) staining</title>
<p>The knee joint tissues were cut to a size of 5 &#xd7; 5 &#xd7; 2 mm and fixed in 10% formalin solution for 24 h. It was then rinsed in running water for 24 h. The tissue was then dehydrated using 85% alcohol once, 95% alcohol twice, anhydrous alcohol twice, anhydrous alcohol and xylene (1:1) once, and pure xylene twice (each for 10 min). The next step was wax immersion and embedding. The same amount of paraffin wax was added, and the tissue was immersed in a 50% paraffin-xylene solution for 10 min, followed by a 100% paraffin solution for a further 10 min. The tissue was immersed in wax at 52&#x2013;56&#xb0;C for 3 h and then embedded in wax at 60&#xb0;C. In the sectioning step, the tissue was sectioned (thickness 5 &#xb5;m), developed, and patched at 42&#xb0;C for 30 min and baked at 60&#xb0;C for 12 h. The tissue was then stained and destained with xylene twice (each for 5 min), 95% ethanol twice (each for 3 min), 80% ethanol once (for 3 min), distilled water once (for 1 min), H&amp;E staining for 5 min, color separation with 1% hydrochloric acid-ethanol for 30 s, 0.5% eosin staining for 1 min, distilled water once (for 1 min), anhydrous ethanol for 5 min, and finally dried at room temperature and sealed with neutral gum. The tissues were observed under a fluorescence microscope, and images were captured using an Eclipse Ci-L microscope (Nikon, Japan).</p>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>Statistical analysis</title>
<p>Graph Pad Prism 8.0 software was used to map and analyze the data. The measurement data were expressed as Mean &#xb1; SD. One-way analysis of variance (ANOVA) was used to compare the means of normal distribution among multiple groups. LSD test was used for comparison between groups. Rank sum test was used for non-normal distribution. P value &lt; 0.05 was considered statistically significant.</p>
</sec>
<sec id="s4" sec-type="results">
<label>4</label>
<title>Results</title>
<sec id="s4_1">
<label>4.1</label>
<title>Drug MIC and minimum bactericidal concentration</title>
<p>The MIC values against PA were as follows: 890 &#xb5;g/mL for DAP, 2 mg/mL for EDTA-2Na, and 2.75 &#xb5;g/mL for TOB. The corresponding MBC for TOB was 5.5 &#xb5;g/mL.</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Quantitative results of BF in different treatment groups <italic>in vitro</italic>
</title>
<p>There was no difference in bacterial growth among the groups before treatment, as shown in <xref
ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref> named &#x201c;before treatment.&#x201d; PA-BF was significantly reduced in the DAP monotherapy, EDTA-2Na (2 mg/mL) + TOB (5.5 &#x3bc;g/mL), and DAP (890 &#x3bc;g/mL) + TOB (5.5 &#x3bc;g/mL) treatment groups compared to the control and TOB monotherapy groups (P &lt; 0.05). However, no statistical difference was observed between the EDTA-2Na+TOB and DAP+TOB combination groups. Consistent with <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, the DMSO solvent control, TOB alone, and untreated control groups showed comparable biofilm levels.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Quantitative results of PA-BF after 24 h of intervention in each group were detected using crystal violet staining <italic>in vitro</italic>. DMSO, dimethyl sulfoxide; TOB, Tobramycin; DAP, Daphnetin; EDTA-2Na, ethylenediaminetetraacetic acid disodium; NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g001.tif">
<alt-text content-type="machine-generated">Bar graph showing biofilm formation (OD&#x2085;&#x2089;&#x2085;) across six conditions: Control, DMSO, TOB, DAP, DAP+TOB, and EDTA-2Na+TOB. DMSO and TOB have similar high levels, while DAP, DAP+TOB, and EDTA-2Na+TOB show reduced levels. Statistical significance is indicated with asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Number of viable bacteria in BFs of different treatment groups <italic>in vitro</italic>
</title>
<p>No significant reduction in viable bacterial counts within BF was observed following 24 h treatment with 5.5 &#x3bc;g/mL TOB alone. In contrast, treatments with DAP monotherapy, EDTA-2Na+TOB, and TOB+DAP all demonstrated significantly lower viable bacterial counts compared to the control group (P &lt; 0.05). The DMSO solvent control, TOB monotherapy, and untreated control groups showed comparable bacterial viability (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Quantitative results of PA-BF after 24 h of intervention in each group were detected using colony counting. DMSO, dimethyl sulfoxide; TOB, Tobramycin; DAP, Daphnetin; EDTA-2Na, ethylenediaminetetraacetic acid disodium; NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g002.tif">
<alt-text content-type="machine-generated">Bar graph showing biofilm colony counts (log CFU/mL) for different treatments: Control, DMSO, TOB, DAP, DAP+TOB, and EDTA-2Na+TOB. Control, DMSO, and TOB have similar high counts around 10. DAP, DAP+TOB, and EDTA-2Na+TOB show progressively lower counts, with EDTA-2Na+TOB being the lowest. Significant differences are indicated with asterisks, and &#x201c;NS&#x201d; denotes non-significant differences.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_4">
<label>4.4</label>
<title>Electron microscopic observation of BF morphology in different treatment groups <italic>in vitro</italic>
</title>
<p>In <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>, the control group showed a significant amount of dense BF formation on the carrier surface. They also secreted some mucilaginous substances that were tightly associated with each other, and the pathogen PA was tightly wrapped in the BF. In <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>, the single TOB group showed a similar amount of BF on the carrier surface, however, the number of PA decreased slightly, and it could be considered that the planktonic cells were killed by TOB. In the DAP alone group (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>), the BF on the surface of the carrier reduced significantly, but there were still several bacteria attached to the carrier surface and some BF-like substances on the bacterial surface. In contrast, carriers in both the DAP+TOB group (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>) and EDTA-2Na+TOB group (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E</bold>
</xref>) showed complete absence of biofilm structures, with only sparse individual bacteria observed. Quantitative electron microscopy analysis (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3F</bold>
</xref>) confirmed significant reductions in biofilm bacterial counts for the DAP monotherapy, DAP+TOB, and EDTA-2Na+TOB treatment groups compared to controls.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>SEM observation of PA-BF after 24 h of intervention in each group. <bold>(A)</bold> control group; <bold>(B)</bold> TOB group; <bold>(C)</bold> DAP group; <bold>(D)</bold> TOB + DAP group. <bold>(E)</bold> EDTA-2Na+TOB; <bold>(F)</bold> Quantitative electron microscopy analysis. TOB, Tobramycin; DAP, Daphnetin; EDTA-2Na, ethylenediaminetetraacetic acid disodium. NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g003.tif">
<alt-text content-type="machine-generated">Five electron micrographs (A to E) and one bar chart (F). Micrographs show different bacterial formations on surfaces at a scale of 10 micrometers. A shows dense bacterial coverage; B features a mix of bacteria and debris. C and D show reduced bacterial coverage with some individual cells. E displays minimal bacterial presence. The bar chart (F) compares biofilm bacterial counts across different treatments: control, TOB, DAP, DAP+TOB, and EDTA+TOB, indicating significant reductions, particularly in EDTA+TOB, with key differences marked by asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_5">
<label>4.5</label>
<title>General condition of the rabbits <italic>in vivo</italic> and anatomical observation of the knee joint</title>
<p>On day 14 of the experiment, the fluid from the affected knee joint was collected for bacterial culture and drug susceptibility testing. The results showed that PA was infected and sensitive to TOB, confirming the success of the suppurative knee joint infection model. All 16 rabbits survived throughout the experiment. In the control and DAP groups, the rabbits gradually lost their appetite and activity during the treatment. Their knee joints became swollen and painful, and had flexion contractures. In contrast, the rabbits in the TOB and TOB + DAP groups had better appetite and activity than those in the control group, with the TOB + DAP group being the best. When the knee joints were examined, the control and DAP groups had a large amount of purulent secretions and debris in the joint cavity and severe congestion of the synovium. Meanwhile, the TOB group had a moderate amount of purulent secretions and debris, with moderate synovial congestion. Finally, the TOB + DAP group had a small amount of purulent secretions and flakes with a small amount of synovial congestion, as shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Observation of gross anatomy of rabbit knee joint on day 4 after <italic>in vivo</italic> treatment. <bold>(A)</bold> control group; <bold>(B)</bold> TOB group; <bold>(C)</bold> DAP group; <bold>(D)</bold> TOB + DAP group. TOB, Tobramycin; DAP, Daphnetin.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g004.tif">
<alt-text content-type="machine-generated">A series of four images labeled A to D, each showing a surgical exposure of a joint on an animal specimen. The images highlight different views and conditions of the anatomical structures against a blue surgical drape background.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_6">
<label>4.6</label>
<title>The results of PA-BF flocculation were observed and quantified using PNA-FISH</title>
<p>In <xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5A, B</bold>
</xref>, representing the control and the TOB groups, respectively, a significant amount of red fluorescence (PA) was surrounded by blue fluorescence (matrix), indicating the presence of BF aggregates embedded in the matrix. However, in <xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5C, D</bold>
</xref>, representing the DAP and DAP + TOB groups, respectively, the amount of BF was less than that of the control and TOB groups. The combined group had the least amount of BF. After analyzing the images using Image-Pro Plus 6.0 software, it was found that the amount of BF in the control and the TOB groups was significantly more than that in the DAP and the combined groups (P &lt; 0.05), as shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5E</bold>
</xref>.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Observation of BF in floccules using PNA-FISH on day 4 after <italic>in vivo</italic> treatment. The PNA-FISH kit uses PA-specific probes (red) and non-specific nucleic acid staining DAPI (blue) to identify BF (&#xd7; 40). <bold>(A)</bold> control group; <bold>(B)</bold> TOB group; <bold>(C)</bold> DAP group; <bold>(D)</bold> DAP and TOB group. TOB, Tobramycin; DAP, Daphnetin; NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g005.tif">
<alt-text content-type="machine-generated">Four fluorescence microscopy images labeled A to D show varying concentrations of cellular material, with pink indicating specific staining within a blue background. Image A depicts a large, dense structure, while B and C show less dense regions. Image D has the least pink staining. Image E is a bar chart comparing the area measurements of the structures across conditions: control, TOB, DAP, and TOB+DAP, with significant differences marked by asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_7" sec-type="results">
<label>4.7</label>
<title>Results of <italic>in vivo</italic> flocculation colony counting</title>
<p>The results of the experiment were as follows: the colony counts of each group were expressed as Lg CFU/mL, g, and are presented as mean &#xb1; SD. The control group had a count of 7.208 &#xb1; 0.11, the DAP group had a count of 7.215 &#xb1; 0.12, the TOB group had a count of 5.945 &#xb1; 0.45, and the TOB + DAP group had a count of 3.465 &#xb1; 0.18. There was no significant difference between the DAP and the control groups (P &gt; 0.05). However, there was a significant difference between the other groups and the control group (P &lt; 0.05), as shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>The results of flocculent colony count on day 4 after <italic>in vivo</italic> treatment. TOB, Tobramycin; DAP, Daphnetin, NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g006.tif">
<alt-text content-type="machine-generated">Bar graph showing Lg CFU/mL, g for four groups: control, DAP, TOB, and TOB+DAP. The control and DAP groups have similar values around 7.5, labeled as not significant (NS). TOB is lower, and TOB+DAP is the lowest at about 5, with significant differences indicated by asterisks (*).</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_8" sec-type="results">
<label>4.8</label>
<title>Results of H&amp;E staining of rabbit knee joint histopathology <italic>in vivo</italic>
</title>
<p>
<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7</bold>
</xref>, <xref ref-type="fig" rid="f8">
<bold>8</bold>
</xref> show that the control and DAP groups had high levels of inflammatory cell infiltration. Moderate inflammatory cell infiltration was observed in the TOB group, and mild inflammatory cell infiltration was observed in the TOB + DAP group. The thickness of the prepatellar synovium was measured in each group (mean &#xb1; SD), as shown in <xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9</bold>
</xref>. The control group had a thickness of 3.120 &#xb1; 0.65 mm, the DAP group had a thickness of 3.176 &#xb1; 0.56 mm, the TOB group had a thickness of 1.668 &#xb1; 0.43 mm, and the TOB + 0.890 &#xb5;g/mL DAP group had a thickness of 0.922 &#xb1; 0.11 mm. There was no significant difference between the DAP and control groups (P &gt; 0.05). However, there was a significant difference between the other groups and the control group (P &lt; 0.05).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Pathological changes in the synovium of the rabbit knee joint after 4 days of treatment (H&amp;E staining, &#xd7; 20). <bold>(A)</bold> control group; <bold>(B)</bold> DAP group; <bold>(C)</bold> TOB group; <bold>(D)</bold> TOB + DAP group. TOB, Tobramycin; DAP, Daphnetin.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g007.tif">
<alt-text content-type="machine-generated">Histological images labeled A, B, C, and D show tissue samples stained pink and purple. Each sample displays varying textures and structures, with differences in density and pattern. The scale is marked at one thousand micrometers for reference.</alt-text>
</graphic>
</fig>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Pathological changes in the synovium of the rabbit knee joint after 4 days of treatment (H&amp;E staining, &#xd7; 400). <bold>(A)</bold> control group; <bold>(B)</bold> DAP group; <bold>(C)</bold> TOB group; <bold>(D)</bold> TOB + DAP group. TOB, Tobramycin; DAP, Daphnetin.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g008.tif">
<alt-text content-type="machine-generated">Histological images comparing tissue samples at high magnification. Panel A shows dense cellular infiltrate. Panel B displays a cluster of cells with increased density. Panel C illustrates less cellularity with more background matrix. Panel D shows adipose tissue with large, clear spaces. All panels are stained with hematoxylin and eosin, scale bar 50 micrometers.</alt-text>
</graphic>
</fig>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>The thickness of the anterior patellar synovium of the rabbit knee was measured under the H&amp;E staining microscope on day 4 after <italic>in vivo</italic> treatment. TOB, Tobramycin; DAP, Daphnetin; NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g009.tif">
<alt-text content-type="machine-generated">Bar graph comparing synovial membrane thickness in millimeters across four groups: Control, DAP, TOB, and TOB+DAP. Control and DAP show similar thickness, labeled NS for not significant. TOB and TOB+DAP show significantly reduced thickness, indicated by asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4_9">
<label>4.9</label>
<title>Systemic toxicity assessment in rabbits</title>
<p>All rabbits survived the experimental period. Body weights (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10A</bold>
</xref>) and serum alanine aminotransferase (ALT) (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10B</bold>
</xref>) and creatinine levels (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10C</bold>
</xref>) were measured on days 1, 7, and 14. Results indicated: Weight changes: Control group showed minor weight reduction, while treatment groups remained unaffected. Biomarkers: All creatinine and ALT values fluctuated within physiologically normal ranges without significant alterations. No treatment-related systemic toxicity was observed.</p>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>Rabbit body weight and serum biomarkers (ALT, Creatinine) at Days 1, 7, and 14. TOB, Tobramycin; DAP, Daphnetin.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1648096-g010.tif">
<alt-text content-type="machine-generated">Three line graphs labeled A, B, and C, comparing groups: control, DAP, TOB, and DAP+TOB over time. A shows weight changes (kg) from baseline to 14 days; B shows alanine aminotransferase levels; C shows creatinine levels (mg/dL). All graphs have similar trends across time points with slight variations among groups.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s5" sec-type="discussion">
<label>5</label>
<title>Discussion</title>
<p>Septic arthritis (SA) is a type of arthritis caused by direct infection with purulent bacteria, resulting in joint destruction and loss of function (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). One of the major challenges in the treatment of SA is bacterial resistance caused by antibiotic tolerance mechanisms such as the formation of pathogenic bacterial BF (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). PA is a common bacterium that causes SA in hospitals and is a highly invasive pathogen that poses a threat to public health due to its virulence factors, BFs, and multidrug resistance (<xref ref-type="bibr" rid="B34">34</xref>). The emergence of multidrug-resistant bacteria has made clinical anti-infective treatment more challenging, leading to the investigation of combination therapy as a potential solution (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). In this context, 7,8-dihydroxycoumarin (DAP) is a traditional Chinese medicine that has anti-inflammatory (<xref ref-type="bibr" rid="B22">22</xref>), anti-osteoarthritic (<xref ref-type="bibr" rid="B25">25</xref>), and inhibitory effects on <italic>R. solanacearum</italic> BF (<xref ref-type="bibr" rid="B23">23</xref>) and PA-BF destruction (<xref ref-type="bibr" rid="B24">24</xref>). In a previous study, the researchers successfully constructed three PA-BF models of SA using PAO1, PAO1<italic>&#x394;wspF</italic> strain with high expression of c-di-GMP, and PAO1/<italic>p<sub>lac</sub>-yhjH</italic> strain with low expression of c-di-GMP (<xref ref-type="bibr" rid="B19">19</xref>). In this study, the researchers investigated the inhibitory effect of DAP combined with TOB on PA-BFs both <italic>in vitro</italic> and <italic>in vivo</italic>. Inhalation of TOB is the preferred maintenance therapy for chronic PA infection (<xref ref-type="bibr" rid="B35">35</xref>). However, the emergence of resistance to this antibiotic&#x2014;including among PA strains&#x2014;has prompted efforts to enhance its efficacy. Researchers now explore liposomal formulations that chemically conjugate or physically encapsulate TOB with other bioactive molecules (<xref ref-type="bibr" rid="B36">36</xref>). Given high resistance rates, TOB is unsuitable as empirical first-line therapy for severe Gram-negative bacterial infections, particularly in high-resistance regions or high-risk patients. Compared to macrolides, colistin, polymyxin B, &#x3b2;-lactams, and fluoroquinolones, TOB demonstrates superior bactericidal activity with lower nephrotoxicity and neurotoxicity. These properties justify its selection as the antibiotic for this study.</p>
<p>The study found that the combination of DAP and TOB had a positive antibacterial effect on PA. Previous research has also shown that quinazolinone (QZN) 34 combined with TOB has antibacterial activity against PA (<xref ref-type="bibr" rid="B37">37</xref>), which supports the conclusions of this study. Although commonly used antibiotics, such as TOB, are effective against PA in the free state, they are not effective against PA in the BF state. However, the combination of TOB and DAP showed a synergistic inhibitory effect against BF bacteria. This could be due to the disruption of the BF structure by DAP, the enhanced penetration ability of TOB into BF, and the improved killing ability of TOB against BF bacteria. In this study, it was observed that the number of viable bacteria in BF was significantly lower after DAP + TOB acted on the BF of PA <italic>in vitro</italic> for 24 h or <italic>in vivo</italic> for 7 days. DAP has the effect of destroying the BF, which is consistent with previous studies. In addition, electron microscopy results showed that the proportion of dead bacteria was higher for DAP + TOB treatment than for the control and TOB groups. The killing effect of DAP alone on PA was weak, but it significantly destroyed the structure of BF. TOB was still effective against PA, and when combined with DAP, its killing effect on PA was significantly improved. DMSO (DAP solvent) diluted 100 times did not affect the growth of PA.</p>
<p>The results of the <italic>in vivo</italic> experiments showed that the control and DAP groups had a numerous of purulent secretions, floccules, severe synovial hyperemia, more bacterial colony counts, and extensive inflammatory cell infiltration on pathological examination. In contrast, the TOB + DAP group had the mildest signs of infection, the lowest bacterial colony count of flocules, and the least inflammatory cell infiltration on pathological examination. This indicates that a concentration of 0.890 mg/mL of DAP alone had no bactericidal effect, but had a synergistic effect with TOB. DAP destroys the PA-BF, which increases the sensitivity of TOB to PA, consistent with the <italic>in vitro</italic> study results. Current antibacterial drugs are not effective against PA-BF infection and it is usually necessary to combine them with other QS inhibitors to enhance their effect. For example, the use of curcumin in combination with sub-inhibitory concentrations of azithromycin, ceftazidime, or ciprofloxacin has been observed to enhance the inhibitory effect on PA-BF formation (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Li et&#xa0;al. (<xref ref-type="bibr" rid="B40">40</xref>) demonstrated the synergistic effect of berberine as a QS inhibitor and azithromycin on PA. Christensen et&#xa0;al. (<xref ref-type="bibr" rid="B41">41</xref>) showed that garlicene, furanone C-30, and horseradish juice extracts as QS inhibitors combined with TOB had a synergistic anti-PA-BF effect. Recent studies have also shown that phytochemicals, such as cinnamic acid (<xref ref-type="bibr" rid="B42">42</xref>), 6-methylcoumarin (<xref ref-type="bibr" rid="B43">43</xref>), sesamin, and sesamolin (<xref ref-type="bibr" rid="B44">44</xref>) attenuate QS-regulated virulence and BF formation. They protect <italic>C. elegans</italic> from PA infection and prolong its lifespan. These results are similar to our <italic>in vivo</italic> findings. And our vivo toxicity assessment in rabbits demonstrated no significant effects on body weight or hepatic and renal function biomarkers. However, the sample size of this part of the study is limited, and further studies are needed to verify the effect of DAP combined with TOB on PA-BF infection and to explore the underlying mechanism.</p>
<p>In conclusion, DAP + TOB treatment showed a promising therapeutic effect on PA-BF infection. It is expected that this treatment will be considered a viable option for the treatment of PA-BF infection, paving the way for the potential clinical application of DAP and opening new avenues for clinical anti-infective therapy.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The study was approved by the Medical Ethics Committee of Guangxi Medical University, and all animal experiments were conducted following the committee&#x2019;s guidelines.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>DL: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Formal Analysis, Investigation, Methodology, Resources, Software, Visualization. CM: Formal Analysis, Investigation, Methodology, Resources, Software, Visualization, Writing &#x2013; review &amp; editing. SC: Investigation, Resources, Writing &#x2013; review &amp; editing. ZW: Investigation, Resources, Writing &#x2013; review &amp; editing. WZ: Investigation, Software, Writing &#x2013; review &amp; editing. ZL: Investigation, Software, Writing &#x2013; review &amp; editing. LL: Investigation, Software, Writing &#x2013; review &amp; editing. CH: Investigation, Software, Writing &#x2013; review &amp; editing. WG: Investigation, Writing &#x2013; review &amp; editing. JW: Conceptualization, Data curation, Methodology, Project administration, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. QW: Conceptualization, Data curation, Methodology, Project administration, Resources, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>I would like to express my gratitude to Ke Wang, Jiahui Wang, and Wusheng Deng. They have helped me directly and indirectly in my studies.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1648096/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1648096/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image1.tif" id="SM1" mimetype="image/tiff">
<label>Supplementary material 1</label>
<caption>
<p>Quantitative results of PA growth for 72 h detected using a microplate reader. Note: NS showed no statistical significance compared with the control group, P &gt; 0.05. * shows that compared with the control group, with statistical significance of P &lt; 0.05.</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beutler</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>EY</given-names>
</name>
</person-group>. <article-title>Septic arthritis: current concepts</article-title>. <source>Semin Musculoskelet Radiol</source>. (<year>2025</year>) <volume>29</volume>:<fpage>293</fpage>&#x2013;<lpage>301</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1055/s-0045-1802352</pub-id>, PMID: <pub-id pub-id-type="pmid">40164084</pub-id></citation></ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margaryan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Renz</surname> <given-names>N</given-names>
</name>
<name>
<surname>Gwinner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Trampuz</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Septic arthritis of the native joint and after ligamentoplasty: Diagnosis and treatment</article-title>. <source>Orthopade</source>. (<year>2020</year>) <volume>49</volume>:<page-range>660&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00132-020-03961-1</pub-id>, PMID: <pub-id pub-id-type="pmid">32737513</pub-id></citation></ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsissy</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>JN</given-names>
</name>
<name>
<surname>Wilton</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Nwachuku</surname> <given-names>I</given-names>
</name>
<name>
<surname>Gowd</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Amin</surname> <given-names>NH</given-names>
</name>
</person-group>. <article-title>Bacterial septic arthritis of the adult native knee joint: A review</article-title>. <source>JBJS Rev</source>. (<year>2020</year>) <volume>8</volume>:<fpage>e0059</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2106/JBJS.RVW.19.00059</pub-id>, PMID: <pub-id pub-id-type="pmid">31899698</pub-id></citation></ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Novel therapeutic interventions towards improved management of septic arthritis</article-title>. <source>BMC Musculoskelet Disord</source>. (<year>2021</year>) <volume>22</volume>:<fpage>530</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12891-021-04383-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34107951</pub-id></citation></ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Tabassum</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>YM</given-names>
</name>
</person-group>. <article-title>Natural and synthetic molecules with potential to enhance biofilm formation and virulence properties in <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Crit Rev Microbiol</source>. (<year>2024</year>) <volume>50</volume>:<page-range>830&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/1040841X.2023.2282459</pub-id>, PMID: <pub-id pub-id-type="pmid">37968960</pub-id></citation></ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murillo</surname> <given-names>O</given-names>
</name>
<name>
<surname>Gomez-Junyent</surname> <given-names>J</given-names>
</name>
<name>
<surname>Grau</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ribera</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cabrera</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pedrero</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical findings of bacteremic septic arthritis according to the site of acquisition: The overlap between health care-related and community- and nosocomial-acquired cases</article-title>. <source>Eur J Intern Med</source>. (<year>2016</year>) <volume>28</volume>:<fpage>38</fpage>&#x2013;<lpage>42</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejim.2015.11.013</pub-id>, PMID: <pub-id pub-id-type="pmid">26639050</pub-id></citation></ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodr&#xed;guez-Urretavizcaya</surname> <given-names>B</given-names>
</name>
<name>
<surname>Vilaplana</surname> <given-names>L</given-names>
</name>
<name>
<surname>Marco</surname> <given-names>MP</given-names>
</name>
</person-group>. <article-title>Strategies for quorum sensing inhibition as a tool for controlling <italic>Pseudomonas aeruginosa</italic> infections</article-title>. <source>Int J Antimicrob Agents</source>. (<year>2024</year>) <volume>64</volume>:<elocation-id>107323</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2024.107323</pub-id>, PMID: <pub-id pub-id-type="pmid">39242051</pub-id></citation></ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laborda</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sanz-Garc&#xed;a</surname> <given-names>F</given-names>
</name>
<name>
<surname>Hernando-Amado</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mart&#xed;nez</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>
<italic>Pseudomonas aeruginosa</italic>: an antibiotic resilient pathogen with environmental origin</article-title>. <source>Curr Opin Microbiol</source>. (<year>2021</year>) <volume>64</volume>:<page-range>125&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mib.2021.09.010</pub-id>, PMID: <pub-id pub-id-type="pmid">34710741</pub-id></citation></ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soukarieh</surname> <given-names>F</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>P</given-names>
</name>
<name>
<surname>Stocks</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>C&#xe1;mara</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>
<italic>Pseudomonas aeruginosa</italic> quorum sensing systems as drug discovery targets: current position and future perspectives</article-title>. <source>J Med Chem</source>. (<year>2018</year>) <volume>61</volume>:<page-range>10385&#x2013;402</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00540</pub-id>, PMID: <pub-id pub-id-type="pmid">29999316</pub-id></citation></ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soukarieh</surname> <given-names>F</given-names>
</name>
<name>
<surname>Vico Oton</surname> <given-names>E</given-names>
</name>
<name>
<surname>Dubern</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Gomes</surname> <given-names>J</given-names>
</name>
<name>
<surname>Halliday</surname> <given-names>N</given-names>
</name>
<name>
<surname>de Pilar Crespo</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>In silico and <italic>in vitro</italic>-guided identification of inhibitors of alkylquinolone-dependent quorum sensing in <italic>pseudomonas aeruginosa</italic>
</article-title>. <source>Molecules</source>. (<year>2018</year>) <volume>23</volume>:<elocation-id>257</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/molecules23020257</pub-id>, PMID: <pub-id pub-id-type="pmid">29382099</pub-id></citation></ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cendra</surname> <given-names>MDM</given-names>
</name>
<name>
<surname>Torrents</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>
<italic>Pseudomonas aeruginosa</italic> biofilms and their partners in crime</article-title>. <source>Biotechnol Adv</source>. (<year>2021</year>) <volume>49</volume>:<elocation-id>107734</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bioteChadv.2021.107734</pub-id>, PMID: <pub-id pub-id-type="pmid">33785375</pub-id></citation></ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paluch</surname> <given-names>E</given-names>
</name>
<name>
<surname>Rewak-Soroczy&#x144;ska</surname> <given-names>J</given-names>
</name>
<name>
<surname>J&#x119;drusik</surname> <given-names>I</given-names>
</name>
<name>
<surname>Mazurkiewicz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Jermakow</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Prevention of biofilm formation by quorum quenching</article-title>. <source>Appl Microbiol Biotechnol</source>. (<year>2020</year>) <volume>104</volume>:<page-range>1871&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00253-020-10349-w</pub-id>, PMID: <pub-id pub-id-type="pmid">31927762</pub-id></citation></ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname> <given-names>D</given-names>
</name>
<name>
<surname>Misba</surname> <given-names>L</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>AU</given-names>
</name>
</person-group>. <article-title>Antibiotics versus biofilm: an emerging battleground in microbial communities</article-title>. <source>Antimicrob Resist Infect Control</source>. (<year>2019</year>) <volume>8</volume>:<fpage>76</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13756-019-0533-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31131107</pub-id></citation></ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmati</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nazari</surname> <given-names>M</given-names>
</name>
<name>
<surname>Abolhasani</surname> <given-names>FS</given-names>
</name>
<name>
<surname>Ahmadi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Asghari</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>In vitro investigation of relationship between quorum-sensing system genes, biofilm forming ability, and drug resistance in clinical isolates of <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>BMC Microbiol</source>. (<year>2024</year>) <volume>24</volume>(<issue>1</issue>):<fpage>99</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12866-024-03249-w</pub-id>, PMID: <pub-id pub-id-type="pmid">38528442</pub-id></citation></ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saraswathi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Beuerman</surname> <given-names>RW</given-names>
</name>
</person-group>. <article-title>Corneal biofilms: from planktonic to microcolony formation in an experimental keratitis infection with <italic>pseudomonas aeruginosa</italic>
</article-title>. <source>Ocul Surf</source>. (<year>2015</year>) <volume>13</volume>:<page-range>331&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jtos.2015.07.001</pub-id>, PMID: <pub-id pub-id-type="pmid">26220579</pub-id></citation></ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>The effect of Cyclic-di-GMP on biofilm formation by <italic>Pseudomonas aeruginosa</italic> in a novel empyema model</article-title>. <source>Ann Transl Med</source>. (<year>2020</year>) <volume>8</volume>:<fpage>1146</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/atm-20-6022</pub-id>, PMID: <pub-id pub-id-type="pmid">33240995</pub-id></citation></ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kania</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Lamers</surname> <given-names>GE</given-names>
</name>
<name>
<surname>Vonk</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Huy</surname> <given-names>PT</given-names>
</name>
<name>
<surname>Hiemstra</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Bloemberg</surname> <given-names>GV</given-names>
</name>
<etal/>
</person-group>. <article-title>Demonstration of bacterial cells and glycocalyx in biofilms on human tonsils</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. (<year>2007</year>) <volume>133</volume>:<page-range>115&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/archotol.133.2.115</pub-id>, PMID: <pub-id pub-id-type="pmid">17309977</pub-id></citation></ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall-Stoodley</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>FZ</given-names>
</name>
<name>
<surname>Gieseke</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nistico</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hayes</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media</article-title>. <source>JAMA</source>. (<year>2006</year>) <volume>296</volume>:<page-range>202&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.296.2.202</pub-id>, PMID: <pub-id pub-id-type="pmid">16835426</pub-id></citation></ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Biofilm formation by <italic>pseudomonas aeruginosa</italic> in a novel septic arthritis model</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>724113</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2021.724113</pub-id>, PMID: <pub-id pub-id-type="pmid">34621691</pub-id></citation></ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loho</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sukartini</surname> <given-names>N</given-names>
</name>
<name>
<surname>Astrawinata</surname> <given-names>DAW</given-names>
</name>
<name>
<surname>Immanuel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Aulia</surname> <given-names>D</given-names>
</name>
<name>
<surname>Priatni</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>
<italic>In Vitro</italic> Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, <italic>Pseudomonas aeruginosa</italic>, and Klebsiella pneumoniae Isolates</article-title>. <source>Can J Infect Dis Med Microbiol</source>. (<year>2018</year>) <volume>2018</volume>:<elocation-id>1047670</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2018/1047670</pub-id>, PMID: <pub-id pub-id-type="pmid">30065794</pub-id></citation></ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamagishi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hagihara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hirai</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nishiyama</surname> <given-names>N</given-names>
</name>
<name>
<surname>Koizumi</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>
<italic>In vitro</italic> and <italic>in vivo</italic> Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Chemotherapy</source>. (<year>2017</year>) <volume>62</volume>:<page-range>105&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000449367</pub-id>, PMID: <pub-id pub-id-type="pmid">27788502</pub-id></citation></ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhuo</surname> <given-names>S</given-names>
</name>
<name>
<surname>He</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Daphnetin prevents methicillin-resistant <italic>Staphylococcus aureus</italic> infection by inducing autophagic response</article-title>. <source>Int Immunopharmacol</source>. (<year>2019</year>) <volume>72</volume>:<fpage>195</fpage>&#x2013;<lpage>203</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2019.04.007</pub-id>, PMID: <pub-id pub-id-type="pmid">30991161</pub-id></citation></ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>New Insights into the Antibacterial Activity of Hydroxycoumarins against Ralstonia solanacearum</article-title>. <source>Molecules</source>. (<year>2016</year>) <volume>21</volume>:<elocation-id>468</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/molecules21040468</pub-id>, PMID: <pub-id pub-id-type="pmid">27070570</pub-id></citation></ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of daphnetin on biofilm formation and motility of pseudomonas aeruginosa</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>1033540</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2022.1033540</pub-id>, PMID: <pub-id pub-id-type="pmid">36467736</pub-id></citation></ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Chondroprotective and antiarthritic effects of Daphnetin used <italic>in vitro</italic> and <italic>in vivo</italic> osteoarthritis models</article-title>. <source>Life Sci</source>. (<year>2020</year>) <volume>240</volume>:<elocation-id>116857</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.lfs.2019.116857</pub-id>, PMID: <pub-id pub-id-type="pmid">31521691</pub-id></citation></ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Chemoprotective effect of daphnetin in doxorubicin treated esophageal cancer stem cell xenograft tumor mouse</article-title>. <source>Dokl Biochem Biophys</source>. (<year>2021</year>) <volume>499</volume>:<page-range>273&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1134/S1607672921040128</pub-id>, PMID: <pub-id pub-id-type="pmid">34426926</pub-id></citation></ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belanger</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Hancock</surname> <given-names>REW</given-names>
</name>
</person-group>. <article-title>Testing physiologically relevant conditions in minimal inhibitory concentration assays</article-title>. <source>Nat Protoc</source>. (<year>2021</year>) <volume>16</volume>:<page-range>3761&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41596-021-00572-8</pub-id>, PMID: <pub-id pub-id-type="pmid">34215865</pub-id></citation></ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chua</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Hultqvist</surname> <given-names>LD</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rybtke</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nielsen</surname> <given-names>TE</given-names>
</name>
<name>
<surname>Givskov</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>
<italic>In vitro</italic> and <italic>in vivo</italic> generation and characterization of <italic>Pseudomonas aeruginosa</italic> biofilm-dispersed cells via c-di-GMP manipulation</article-title>. <source>Nat Protoc</source>. (<year>2015</year>) <volume>10</volume>:<page-range>1165&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nprot.2015.067</pub-id>, PMID: <pub-id pub-id-type="pmid">26158442</pub-id></citation></ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chua</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Rybtke</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Rice</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Kjelleberg</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Bis-(3&#x2019;-5&#x2019;)-cyclic dimeric GMP regulates antimicrobial peptide resistance in <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Antimicrob Agents Chemother</source>. (<year>2013</year>) <volume>57</volume>:<page-range>2066&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/AAC.02499-12</pub-id>, PMID: <pub-id pub-id-type="pmid">23403434</pub-id></citation></ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Antibacterial activity and mechanism of linalool against Pseudomonas aeruginosa</article-title>. <source>Microb Pathog</source>. (<year>2020</year>) <volume>141</volume>:<elocation-id>103980</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.micpath.2020.103980</pub-id>, PMID: <pub-id pub-id-type="pmid">31962183</pub-id></citation></ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haney</surname> <given-names>EF</given-names>
</name>
<name>
<surname>Trimble</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Hancock</surname> <given-names>REW</given-names>
</name>
</person-group>. <article-title>Microtiter plate assays to assess antibiofilm activity against bacteria</article-title>. <source>Nat Protoc</source>. (<year>2021</year>) <volume>16</volume>:<page-range>2615&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41596-021-00515-3</pub-id>, PMID: <pub-id pub-id-type="pmid">33911258</pub-id></citation></ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Aker</surname> <given-names>WG</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Synergistic combination of marine oligosaccharides and azithromycin against Pseudomonas aeruginosa</article-title>. <source>Microbiol Res</source>. (<year>2014</year>) <volume>169</volume>:<page-range>759&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.micres.2014.01.001</pub-id>, PMID: <pub-id pub-id-type="pmid">24529598</pub-id></citation></ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rosca</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Muzny</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Cerca</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Atopobium vaginae and Prevotella bivia Are Able to Incorporate and Influence Gene Expression in a Pre-Formed Gardnerella vaginalis Biofilm</article-title>. <source>Pathogens</source>. (<year>2021</year>) <volume>10</volume>:<elocation-id>247</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pathogens10020247</pub-id>, PMID: <pub-id pub-id-type="pmid">33672647</pub-id></citation></ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynolds</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kollef</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The epidemiology and pathogenesis and treatment of <italic>pseudomonas aeruginosa</italic> infections: an update</article-title>. <source>Drugs</source>. (<year>2021</year>) <volume>81</volume>:<page-range>2117&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40265-021-01635-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34743315</pub-id></citation></ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiel</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Roesch</surname> <given-names>EA</given-names>
</name>
</person-group>. <article-title>The use of tobramycin for Pseudomonas aeruginosa: a review</article-title>. <source>Expert Rev Respir Med</source>. (<year>2022</year>) <volume>16</volume>:<page-range>503&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/17476348.2022.2057951</pub-id>, PMID: <pub-id pub-id-type="pmid">35320051</pub-id></citation></ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alzahrani</surname> <given-names>NM</given-names>
</name>
<name>
<surname>Booq</surname> <given-names>RY</given-names>
</name>
<name>
<surname>Aldossary</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Bakr</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Almughem</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Alfahad</surname> <given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Pharmaceutics</source>. (<year>2022</year>) <volume>14</volume>:<elocation-id>960</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14050960</pub-id>, PMID: <pub-id pub-id-type="pmid">35631547</pub-id></citation></ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Dubern</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Chhabra</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>PA</given-names>
</name>
</person-group>. <article-title>
<italic>Pseudomonas aeruginosa</italic> PQS quorum-sensing system inhibitor with anti-staphylococcal activity sensitizes polymicrobial biofilms to tobramycin</article-title>. <source>Cell Chem Biol</source>. (<year>2022</year>) <volume>29</volume>:<fpage>1187</fpage>&#x2013;<lpage>1199.e6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.chembiol.2022.02.007</pub-id>, PMID: <pub-id pub-id-type="pmid">35259345</pub-id></citation></ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roudashti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zeighami</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mirshahabi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bahari</surname> <given-names>S</given-names>
</name>
<name>
<surname>Soltani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Haghi</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Synergistic activity of sub-inhibitory concentrations of curcumin with ceftazidime and ciprofloxacin against <italic>Pseudomonas aeruginosa</italic> quorum sensing related genes and virulence traits</article-title>. <source>World J Microbiol Biotechnol</source>. (<year>2017</year>) <volume>33</volume>:<fpage>50</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11274-016-2195-0</pub-id>, PMID: <pub-id pub-id-type="pmid">28188589</pub-id></citation></ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bahari</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zeighami</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mirshahabi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Roudashti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Haghi</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Inhibition of <italic>Pseudomonas aeruginosa</italic> quorum sensing by subinhibitory concentrations of curcumin with gentamicin and azithromycin</article-title>. <source>J Glob Antimicrob Resist</source>. (<year>2017</year>) <volume>10</volume>:<page-range>21&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jgar.2017.03.006</pub-id>, PMID: <pub-id pub-id-type="pmid">28591665</pub-id></citation></ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Synergistic activity of berberine with azithromycin against <italic>pseudomonas aeruginosa</italic> isolated from patients with cystic fibrosis of lung <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Cell Physiol Biochem</source>. (<year>2017</year>) <volume>42</volume>:<page-range>1657&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000479411</pub-id>, PMID: <pub-id pub-id-type="pmid">28738346</pub-id></citation></ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname> <given-names>LD</given-names>
</name>
<name>
<surname>van Gennip</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jakobsen</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Alhede</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hougen</surname> <given-names>HP</given-names>
</name>
<name>
<surname>H&#xf8;iby</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against <italic>Pseudomonas aeruginosa</italic> in an intraperitoneal foreign-body infection mouse model</article-title>. <source>J Antimicrob Chemother</source>. (<year>2012</year>) <volume>67</volume>:<page-range>1198&#x2013;206</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jac/dks002</pub-id>, PMID: <pub-id pub-id-type="pmid">22302561</pub-id></citation></ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajkumari</surname> <given-names>J</given-names>
</name>
<name>
<surname>Borkotoky</surname> <given-names>S</given-names>
</name>
<name>
<surname>Murali</surname> <given-names>A</given-names>
</name>
<name>
<surname>Suchiang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mohanty</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Busi</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Cinnamic acid attenuates quorum sensing associated virulence factors and biofilm formation in <italic>Pseudomonas aeruginosa</italic> PAO1</article-title>. <source>Biotechnol Lett</source>. (<year>2018</year>) <volume>40</volume>:<page-range>1087&#x2013;100</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10529-018-2557-9</pub-id>, PMID: <pub-id pub-id-type="pmid">29680931</pub-id></citation></ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajire</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Jain</surname> <given-names>S</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>RP</given-names>
</name>
<name>
<surname>Shastry</surname> <given-names>RP</given-names>
</name>
</person-group>. <article-title>6-Methylcoumarin attenuates quorum sensing and biofilm formation in <italic>Pseudomonas aeruginosa</italic> PAO1 and its applications on solid surface coatings with polyurethane</article-title>. <source>Appl Microbiol Biotechnol</source>. (<year>2021</year>) <volume>105</volume>:<page-range>8647&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00253-021-11637-9</pub-id>, PMID: <pub-id pub-id-type="pmid">34750645</pub-id></citation></ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anju</surname> <given-names>VT</given-names>
</name>
<name>
<surname>Busi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ranganathan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ampasala</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Suchiang</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Sesamin and sesamolin rescues Caenorhabditis elegans from <italic>Pseudomonas aeruginosa</italic> infection through the attenuation of quorum sensing regulated virulence factors</article-title>. <source>Microb Pathog</source>. (<year>2021</year>) <volume>155</volume>:<elocation-id>104912</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.micpath.2021.104912</pub-id>, PMID: <pub-id pub-id-type="pmid">33932548</pub-id></citation></ref>
</ref-list>
</back>
</article>